| |
Tuesday, April 4, 2023 | 10am ET / 7am PT Life sciences leaders are reporting that investments in cloud technology are opening new doors for enhanced productivity, improved time-to-insights, and more. Join this one-hour deep dive into the latest solutions and strategies for successfully accelerating innovation while optimizing costs. Register now.
|
|
Today's Big NewsApr 18, 2023 |
|
May 1 - 3, 2023 | Jersey City, NJ Examine how the current changes to field medical will affect the role moving forward. Only a few weeks left, Register Today!
|
|
| By Nick Paul Taylor Merck & Co. has a new challenger for the chronic cough market: GSK. The British Big Pharma is set to pay $2 billion to buy Bellus Health, securing a late-phase rival to Merck’s stuttering gefapixant program and completing a remarkable, 16-year turnaround for the biotech. |
|
|
|
By Annalee Armstrong After circling around the crop of biotechs ripe for a takeover, Big Pharma companies have finally decided to strike. Merck & Co. made the first jab for Prometheus Biosciences on Sunday, then GSK struck Tuesday. |
By Annalee Armstrong The overhaul of Johnson & Johnson’s infectious disease work, which includes the end of its adult RSV vaccine program, has resulted in expenses of $130 million for the first quarter. |
Sponsored by YPrime Michael Hughes, Chief Product Officer at YPrime discusses the benefits and challenges of eConsent implementation and how to circumvent the biggest barriers to adoption. |
By Annalee Armstrong KRAS inhibitors arrived on the market in May 2021 and December 2022 to much fanfare—but if you ask Eli Lilly’s Loxo unit, the therapies have left much to be desired. |
By Max Bayer J&J is bullish on its pharmaceutical plans after reporting $130 million in restructuring costs in the first quarter due to an overhaul of its infectious disease division. The company believes that progress in both immunology and oncology programs provides a sturdy foundation to build on. |
By Nick Paul Taylor The long wait for clinical data on Kinnate Biopharma’s pan-RAF inhibitors is over—and investors see little to get excited about. |
By Gabrielle Masson As difficult market conditions continue, two European-based biotechs are slashing costs and seeking ways to stay afloat as the end of the road nears. |
By James Waldron Almost exactly a year after Nektar Therapeutics jettisoned 70% of its staff, the biotech is now contracting again. This time, 60% of its San Francisco-based workforce are being laid off as part of a reorganization that will also see the C-suite rejigged and the company focus on immunology. |
By Gabrielle Masson The pressure to perform is building for Affimed as its investigational lymphoma treatment fails to beat current standard-of-care treatments, prompting the German biotech to pursue a new path for its lead asset. |
By Kevin Dunleavy 2022 was all about a return to normalcy from the COVID-19 pandemic. While a few companies continued to reap huge profits from COVID products, others benefited from a return to business as usual operations. It was a tough year for the global economy, but biopharma showed its resilience with all but a few recording revenue gains. |
By Helen Floersh A research team has used the blood of hibernating bears to discover how waxing and waning levels of a protein protect against venous thromboembolism. |
By Annie Burky CHICAGO—Soon after announcing a partnership with Amazon Web Services at HIMSS 2023 on Monday, Royal Philips CEO Roy Jakobs joined other health execs to speak on the importance of strategic innovation. |
By Fraiser Kansteiner A $6.9 billion charge tied to J&J’s talc defense spurred a net earnings loss of $68 million in 2023’s first quarter, the company reported Tuesday. J&J is currently defending itself against tens of thousands of lawsuits claiming its talc-based products cause cancer. |
By Helen Floersh A nearly-decade-long study sponsored by actor Michael J. Fox's foundation has resulted in an assay that could pave the way for early intervention in Parkinson's disease—and maybe even new drugs that can prevent the disease. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we talk about biotech’s top money raisers in 2022. We also cover J&J's talc litigation, prison plans for Elizabeth Holmes and more of this week's top headlines. |
|
|---|
|
|
| ResearchRead the results of a two-phase scale-up strategy used to help decrease risk and ensure consistency in complex dry powder media formulations produced within customers’ specifications and timelines. Sponsored by: Thermo Fisher Scientific |
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
